摘要
目的 分析帕利哌酮用于精神分裂症的价值。方法 对2020年6月-2022年5月本院接诊精神分裂症病人（n=82）进行随机分组，试验和对照组各41人，前者用帕利哌酮，后者用奥氮平。对比不良反应等指标。结果 关于不良反应，试验组的发生率2.44%，和对照组9.76%相比无显著差异（P＞0.05）。关于总有效率，试验组的数据95.12%，和对照组80.49%相比更高（P＜0.05）。关于PANSS评分，疗程结束之时：试验组的数据（45.16±4.28）分，和对照组（67.93±6.41）分相比更低（P＜0.05）。关于PSP评分，疗程结束之时：试验组的数据（86.21±2.57）分，和对照组（76.47±4.13）分相比更高（P＜0.05）。关于用药满意度，试验组的数据97.56%，和对照组78.05%相比更高（P＜0.05）。结论 精神分裂症用帕利哌酮，不良反应更少，疗效更为显著，精神症状缓解也更为迅速，社会功能改善更加明显，用药满意度更高。
关键词： 精神分裂症；不良反应；帕利哌酮；价值
Abstract
Objective To analyze the value of paliperidone in schizophrenia. Methods A total of 82 schizophrenic patients (n=82) admitted to our hospital from June 2020 to May 2022 were randomly divided into experimental group and control group, with 41 patients in each group. The former were treated with paliperidone, and the latter with olanzapine. Adverse reactions and other indicators were compared. Results The incidence of adverse reactions in the experimental group was 2.44%, which was not significantly different from 9.76% in the control group (P>0.05). The total effective rate of the experimental group was 95.12%, which was higher than that of the control group (80.49%, P<0.05). At the end of the course of treatment, the PANSS score of the experimental group (45.16±4.28) was lower than that of the control group (67.93±6.41) (P<0.05). Regarding PSP score, at the end of the course of treatment, the data of the experimental group (86.21±2.57) was higher than that of the control group (76.47±4.13) (P<0.05). The satisfaction rate of the experimental group was 97.56%, which was higher than that of the control group (78.05%, P<0.05). Conclusion The use of paliperidone in schizophrenia has less adverse reactions, more significant curative effect, more rapid relief of mental symptoms, more obvious improvement of social function, and higher drug satisfaction.
Key words： Schizophrenia; Adverse reactions; Paliperidone; Value
参考文献 References
[1] 赵文青. 支持性-表达性团体心理干预联合棕榈酸帕利哌酮治疗急性期首发精神分裂症患者的临床疗效[J]. 医学临床研究,2022,39(5):690-692,696.
[2] 商月骄. 帕利哌酮缓释片与盐酸哌罗匹隆片治疗精神分裂症患者临床疗效观察[J]. 国际精神病学杂志,2022,49(2):256-258.
[3] 张岩,钱雅雯,杨欧,等. 棕榈酸帕利哌酮注射液治疗精神分裂症患者依从性的影响因素分析[J]. 国际精神病学杂志,2022,49(1):31-34,40.
[4] 周争轶,彭四新,朱开元,等. 帕利哌酮缓释片与小剂量喹硫平对康复期精神分裂症患者PANSS评分、认知功能及血清BDNF水平的影响[J].贵州医药,2022,46(1):31-32.
[5] YOSHIMURA, YUSAKU, TAKEDA, TOSHIHIKO, KISHI, YOSHIKI, et al. Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders A Retrospective Multicenter Study[J]. Journal of clinical psychopharmacology,2017,37(3):296-301.
[6] 雷杰鹏,杨丽,张轶杰,等. 帕利哌酮、阿立哌唑及利培酮治疗儿童青少年首发精神分裂症临床疗效的比较研究[J]. 临床合理用药杂志,2021,14(6):46-48.
[7] 鞠宏丽. 帕利哌酮治疗精神分裂症患者的临床效果[J]. 中国药物经济学,2021,16(4):111-114.
[8] 蔡清艳,段明君,简薇,等. 帕利哌酮缓释片与利培酮改善老年精神分裂症患者社会功能的对照研究[J]. 临床精神医学杂志,2021,31(3):221-223.
[9] 郑慧,金金,蔡军,等. 棕榈酸帕利哌酮PP1M治疗精神分裂症的药物经济学研究进展[J]. 实用药物与临床,2021,24(3):270-275.
[10] CLAREA. WHICHER, HERMIONE C. PRICE, PETER PHIRI, et al. The use of liraglutide 3.0 mg daily inthe management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial[J]. Diabetes, obesity & metabolism.,2021,23(6):1262-1271.
[11] 闫丽娜,石磊. 帕利哌酮缓释片治疗精神分裂症的效果及不良反应影响分析[J]. 中外医疗,2022,41(16):100-104.
[12] 甘记兴,李永瑾,庞德兵. 小剂量丙戊酸镁联合帕利哌酮缓释片对精神分裂症患者神经营养因子水平的影响[J]. 中华保健医学杂志,2021,23(4):366-369.